Where Is Nasal Drug Delivery Heading? Five Trends Shaping the Future of the Market

Emerging trends often provide the earliest indication of where a market may be heading. Across nasal drug delivery, shifts in therapeutic focus, patient expectations and development approaches are beginning to reshape how future opportunities are being evaluated.

The Nasal Drug Delivery Landscape Is Changing

The nasal route is no longer viewed as a niche option reserved for a limited number of rescue therapies.

Over the past decade, growing scientific understanding, advances in formulation technology and increasing confidence in intranasal administration have expanded the range of opportunities being explored by pharmaceutical developers. Today, the industry is evaluating nasal delivery for applications ranging from CNS disorders and cardiovascular indications to emergency medicines, specialty therapies, and future biologic products.

This evolution is changing how companies think about product development. The question is no longer simply whether a therapy can be delivered through the nose. Increasingly, developers are asking where nasal delivery can create meaningful value for patients, healthcare systems and commercial programs.

This article explores five trends currently shaping the future of nasal drug delivery and systemic nasal drug delivery programs. While every product follows its own development path, several broader trends are beginning to shape the future direction of the market.

Trend 1: Expansion Beyond Traditional Rescue Therapies

As discussed in our previous article, one of the most visible shifts in the nasal delivery landscape is the expansion beyond traditional rescue therapies. While this trend continues to influence development priorities, it is only one part of a broader transformation occurring across the market.

Perhaps one of the clearest illustrations of this evolution is the emergence of intranasal therapies in psychiatric applications. For many years, the nasal route was primarily associated with emergency and rescue medicines, where rapid administration and ease of use were critical. The successful introduction of a CNS therapy delivered using Aptar Pharma's nasal platform demonstrated that nasal delivery could support entirely different treatment paradigms, helping to broaden industry perceptions of where the route could create value.

That shift in thinking has contributed to growing interest in nasal delivery across a much wider range of therapeutic categories. Today, Aptar Pharma delivery platforms support marketed products spanning seizure rescue, opioid overdose reversal, severe hypoglycaemia, migraine, cardiovascular indications and CNS disorders, reflecting the increasingly diverse applications being explored by developers.

Together, these developments highlight a broader change in perspective. Increasingly, the nasal route is being considered not as a specialized option for emergency use, but as a versatile delivery platform capable of supporting a growing range of therapeutic objectives, from emergency and acute care to psychiatric, CNS and cardiovascular applications.

Trend 2: Growing Interest in CNS and Nose-to-Brain Opportunities

Few areas have generated as much scientific interest as direct nose-to-brain (N2B) delivery.

Researchers continue to investigate how intranasal administration may provide access to the central nervous system while potentially overcoming some of the limitations associated with traditional delivery routes.

Interest extends beyond targeted nose-to-brain approaches. Across the industry, CNS-focused development programs continue to explore intranasal administration for neurological and psychiatric applications where ease of administration, patient convenience and rapid access may provide advantages over existing treatment approaches.

At the same time, increasing investment in neuroscience research, growing interest in non-invasive delivery routes and continued advances in formulation science are helping to expand the range of opportunities being evaluated.

This trend is also driving innovation in delivery technologies. Aptar Pharma's NeuroSpray™ platform reflects the growing industry focus on approaches designed to support delivery to the olfactory region as researchers continue to explore future CNS applications.

While significant scientific and clinical questions remain, few areas are attracting as much long-term research interest as CNS-focused intranasal delivery. As a result, many industry observers expect CNS and nose-to-brain programs to remain a major driver of innovation in nasal drug delivery over the coming decade.

Trend 3: The Rise of Patient-Administered Therapies

Among available non-invasive delivery routes, nasal administration is particularly well aligned with the growing demand for patient-administered therapies.

Healthcare systems continue to move towards care models that empower patients and reduce dependence on clinical settings whenever appropriate. At the same time, patients increasingly expect treatments that are convenient, portable and easy to integrate into everyday life.

The success of self-administered nasal products across multiple therapeutic areas has helped reinforce the attractiveness of the route. From rescue medicines carried in a patient's pocket to therapies designed for use outside traditional healthcare environments, nasal delivery continues to demonstrate its potential to support patient-centered care.

As a result, patient experience is becoming a strategic consideration much earlier in development programs than was historically the case. For developers, this means evaluating not only pharmacology and device performance, but also administration conditions, training requirements, usability and treatment convenience.

The question is no longer whether patients can self-administer a therapy. Increasingly, the focus is on designing products that fit naturally into the patient's treatment journey.

Trend 4: Platform-Based Development Is Becoming More Important

As development costs, timelines and regulatory complexity continue to increase, pharmaceutical companies are placing greater value on platform-based approaches.

Rather than developing every component from scratch, teams are increasingly seeking to leverage established delivery platforms supported by known performance characteristics and commercial experience.

This trend is particularly visible in nasal drug delivery.

Developers are evaluating not only a delivery system's capabilities, but also the knowledge that comes with it. Regulatory familiarity, validation history, manufacturing readiness and commercial experience can all influence development decisions. Increasingly, companies are recognizing that the value of a platform extends beyond the device itself to include the evidence, development expertise and real-world experience accumulated throughout its lifecycle.

Aptar Pharma's UDS and BDS platforms, for example, have supported marketed products across multiple therapeutic categories and geographic markets. Beyond device performance, this accumulated experience provides insight into the practical realities of developing and commercializing nasal drug products.

Aptar Pharma has also observed that nasal delivery is increasingly being considered alongside more traditional administration routes at the outset of development programs, reflecting growing confidence in the route and the value of established platform experience. As applications become more critical and sophisticated, developers are increasingly evaluating not only innovative features, but also the consistency, reliability and reproducibility of platform performance throughout development and commercialization.

As the market continues to mature, platform knowledge is likely to become an increasingly important differentiator.

Trend 5: Complex Molecules Are Driving New Development Approaches

As the pharmaceutical pipeline continues to diversify, many developers are exploring molecules that present challenges beyond those associated with traditional small-molecule products.

Peptides, proteins, biologics, nucleic-acid-based therapies and other advanced modalities are attracting increasing attention across the industry. While these molecules offer significant therapeutic potential, they also introduce new formulation, stability, delivery and manufacturing considerations.

As a result, development strategies are evolving.

Historically, formulation and device development were often conducted as largely separate activities. Today, the increasing complexity of drug candidates is encouraging a more integrated approach, where formulation scientists, device specialists and regulatory experts collaborate much earlier in development.

This shift is particularly relevant in nasal drug delivery. Product success may depend not only on achieving the desired deposition profile, but also on understanding how formulation characteristics interact with device performance, usability requirements and manufacturing constraints.

Recent work across the industry reflects this change. Aptar Pharma's Nanopharm team has supported programs involving peptides, proteins, antibodies, exosomes, mRNA-loaded lipid nanoparticles and other advanced formulations, highlighting the growing diversity of molecules being evaluated for nasal and pulmonary delivery.

As programs become more complex, developers are increasingly looking for integrated expertise that combines formulation science with delivery-system knowledge from the earliest stages of development.

The implication is clear: future innovation in nasal drug delivery will not be driven solely by new devices or new formulations, but by the ability to successfully integrate both into a cohesive product-development strategy.

Key Takeaways

The future of nasal drug delivery will not be defined by a single therapeutic area, molecule type or delivery format.

While the expansion beyond traditional rescue therapies remains an important market driver, it is occurring alongside several other shifts that are reshaping the market. Growing interest in CNS and nose-to-brain applications, increasing demand for patient-administered therapies, greater reliance on platform-based development strategies and the emergence of increasingly complex molecules are all influencing how developers evaluate future programs.

Taken together, these trends point towards a more diverse and sophisticated nasal delivery landscape than existed just a decade ago. What was once viewed as a niche route for specific emergency applications is increasingly being considered a versatile platform capable of supporting a broad spectrum of therapeutic objectives.

For pharmaceutical developers, understanding these broader market forces may be just as important as evaluating individual technologies. The organizations best positioned to succeed will be those that can connect evolving patient needs, therapeutic opportunities, formulation challenges and development strategies into a coherent product vision. Increasingly, successful programs will depend on combining innovative delivery technologies with formulation expertise, usability considerations and development experience across the entire product lifecycle.

Looking Ahead

As innovation accelerates, regulatory expectations continue to evolve alongside the market. At the same time, developers must navigate an increasingly complex landscape spanning combination products, human factors, platform history, device selection and development strategy.

In our next article, we will explore the regulatory factors that should be considered early when planning a nasal drug-delivery program, and how these decisions can influence development timelines, risk profiles and long-term commercial success.